Repeated Botox treatments led to progressive improvement in static glabellar lines

CHICAGO — Patients repeatedly treated with Botox over the long term displayed a progressive improvement in static glabellar lines, according to research presented at the American Society for Dermatologic Surgery annual meeting.

“This study amplifies the positive effects of injectable neuromodulators in long-term use in the glabella," Alastair Carruthers, FRCPC, told Healio.com.

Carruthers and colleagues presented a study in which pooled data were extracted from repeat-treatment clinical trials originally designed to measure dynamic glabellar lines. There were 258 participants aged 18 to 75 years with at least moderate glabellar lines during animation who received three treatments of 20 U Botox (onabotulinumtoxinA, Allergan) 4 months apart. A validated photo numeric Facial Wrinkle Scale (FWS; 0 = none to 3 = severe) was used to measure lines.

Alastair Carruthers

There were 225 patients with at least mild static lines (FWS ≥ 1) included in the analysis. Patients who achieved elimination of static glabellar lines (FWS = 0) on day 7, 30, 60, 90 or 120 were considered responders. Cochran-Armitage tests measured age group trends.

The majority of patients were female (85%), white (88%) and ranged in age from 35 to 54 years with a baseline FWS score of 1 at rest. Seventy-six percent of patients responded after one treatment, while 45% of patients responded in all three treatment cycles.

“The likelihood of resounding significantly improved with increasing number of treatments for all participants combined (OR = 1.31; P < .001), for participants with mild static lines at baseline (OR = 1.49; P <.01), and for older women (>55 years) with mild static lines at baseline (OR = 2.22; P <.01),” the researchers wrote.

The percentage of responders in all three cycles declined with age among women with mild static lines at baseline (P = .02).

“These results can help aesthetic clinicians provide more effective guidance to patients regarding potential treatment outcomes and help create tailored treatment algorithms and long-term treatment plans to obtain treatment outcomes for both dynamic and static lines,” the researchers concluded. – by Bruce Thiel

Reference:

Carruthers A. OA308. Repeated OnabotulinumtoxinA Treatment for Static Glabellar Lines Over Three Treatment Cycles. Presented at: ASDS Annual Meeting; Oct. 15-18, 2015; Chicago.

Disclosure: Carruthers reports serving as consultant for Allergan, Merz and Kythera, and being an investigator for Evolus and Revance.